Search

Background Because long non-coding RNA ATB (activated by TGF-β) is dysregulated in many cancers, we performed a meta-analysis to determine its prognostic potential in malignant tumors. Methods We searched electronic databases, including PubMed, Medline, OVID, Cochrane Library and Web of Science from inception until November 15, 2016 and identified eight studies with 818 cancer patients for the meta-analysis. We analyzed the hazard ratios (HRs) and 95% confidence intervals (CIs) to determine the relationship between lncRNA-ATB expression and overall survival (OS), recurrence -free survival (RFS), disease-free survival (DFS). We also use RevMan5.3 software to calculate odds ratio (ORs) to assess the association between lncRNA-ATB expression and pathological parameters including lymph node metastasis (LNM), distant metastasis (DM) and tumor stage. Results Our analysis showed that increased lncRNA-ATB expression was associated with OS (HR = 2.82, 95% CI:1.98–4.00, P < 0.00001), DFS (HR = 2.75, 95% CI:1.73–4.38, P < 0.0001), RFS(HR = 3.96, 95% CI:2.30–6.81, P < 0.00001), LNM (OR = 4.07, 95% CI 1.74–9.53, P = 0.001), DM (OR = 3.21, 95% CI 1.06–9.72, P = 0.04) and high tumor stage (OR = 2.81, 95% 1.78–4.43, P < 0.0001) in patients with other types of cancers that excluded pancreatic cancer. Conclusions Meta-analysis demonstrated that increased lncRNA-ATB expression can be a useful prognostic biomarker in human cancer. [ABSTRACT FROM AUTHOR]

Background It has been reported that Colon cancer-associated transcript 2 (CCAT2) is dysregulated in various cancers. We performed this meta-analysis to clarify its promising functions as a prognosis marker in malignant tumors. Methods Electronic databases, including PubMed, Medline, OVID, Cochrane Library, and Web of Science, were searched from inception to October 20, 2016. The hazard ratio (HR) and 95% confidence interval (CI) were calculated to explore the relationship between CCAT2 expression and survival, which were extracted from the eligible studies. The odds ratio (OR) was calculated to assess the association between CCAT2 expression and pathological parameters using RevMan5.3 software. Results Six original studies were included in this meta-analysis including 725 cancer patients. The pooled HR suggested that high CCAT2 expression was significantly correlated with overall survival (OS) (HR = 2.30, 95% CI: 1.62–3.25, p < 0.00001) in cancer patients. Subgroup analysis revealed a significant association between CCAT2 and OS in urogenital system (HR = 1.70, 95% CI: 1.27–2.26, p < 0.003) and non-urogenital system cancer patients (HR = 3.18, 95% CI: 2.09–4.83, p < 0.0001). A significant association was observed between high CCAT2 expression and poor progression-free survival (PFS) in cancer patients (pooled HR = 2.76, 95% CI: 1.74–4.37). CCAT2 expression was significantly related to lymph node metastasis (LNM) (OR = 4.33, 95% CI 2.03–9.22), distant metastasis (DM) (OR = 11.66, 95% CI: 5.36–25.37) and tumor stage (OR = 2.58, 95% CI 1.86–3.57). Conclusions This meta-analysis demonstrated that high CCAT2 expression significantly predicts poor OS, poor PFS, LNM, DM and tumor stage, suggesting that high CCAT2 expression may serve as a novel biomarker for poor prognosis and metastasis in cancers. [ABSTRACT FROM AUTHOR]